We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Avidity Biosciences Inc (RNA) USD0.0001

Sell:$44.50 Buy:$46.19 Change: $1.31 (2.85%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Sell:$44.50
Buy:$46.19
Change: $1.31 (2.85%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Sell:$44.50
Buy:$46.19
Change: $1.31 (2.85%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Contact details

Address:
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO
92121
United States
Telephone:
+1 (858) 4017900
Website:
https://www.aviditybiosciences.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RNA
ISIN:
US05370A1088
Market cap:
$4.91 billion
Shares in issue:
106.14 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Sarah Boyce
    President, Chief Executive Officer, Director
  • Michael Maclean
    Chief Financial and Chief Business Officer
  • Teresa Mccarthy
    Chief Human Resource Officer
  • W. Michael Flanagan
    Chief Scientific and Technical Officer
  • Arthur Levin
    Distinguished Scientist and Strategic Leader, Director
  • Eric Mosbrooker
    Chief Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.